Please login to the form below

Not currently logged in
Email:
Password:

Embeda

This page shows the latest Embeda news and features for those working in and with pharma, biotech and healthcare.

FDA panel backs Pfizer and Teva abuse-resistant painkillers

FDA panel backs Pfizer and Teva abuse-resistant painkillers

Pfizer already sells an abuse-resistant formulation of morphine called Embeda, which uses the same naltrexone technology and was awarded an oral and intranasal abuse claim in 2014, but without an

Latest news

  • Opioid analgesics

    Pfizer's Embeda combines morphine and naltrexone in a single extended-release capsule. ... This, combined with the post-marketing data, suggest that Embeda is providing much-needed pain relief in this patient population without exposure to the risk of

  • Pfizer to buy King for $3.6bn

    sprains and bruises; and Embeda (morphine sulphate/ naltrexone hydrochloride), which was approved in August of this year as the first long-acting opioid that is designed to reduce drug liking and

  • King's profits hit by generic competition

    Its pain drug Embeda (morphine sulfate and naltrexone hydrochloride) is showing continued growth since it launched in September 2010 and reaped $15m during the second quarter.

  • Clouded vision

    EMBEDA (King Pharmaceuticals). Moderate to severe chronic pain . US. Oxycodone hydrochloride.

  • King Pharma announce unexpected profit

    The company is currently focusing on gaining regulatory approvals for its trio of opioid products for treating late-stage pain: Remoxy, an extended-release oxycodone drug, Embeda, an extended-release morphine

More from news
Approximately 1 fully matching, plus 5 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Spirit, an OPEN Health Company

We find the soul in the science, the humanity in the data, harnessing the power of creativity to deliver medical...

Latest intelligence

Robust Review: COVID19 Assessment
See how our client utilized Rapid Payer Response (RPR) to stay informed and gain continuous insights during the recent global pandemic (COVID19)...
Human behaviour - Sept 21
All change – how untangling human behaviour can encourage better health
Driving better patient outcomes through clear, achievable practical steps that are underpinned by transparent evidence...
Health literacy in the time of COVID-19
In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...